{"meshTagsMajor":["Drug Resistance, Neoplasm"],"meshTags":["Antineoplastic Agents","Drug Resistance, Neoplasm","Genes, ras","Humans","Indoles","Melanoma","Protein Kinase Inhibitors","Protein-Serine-Threonine Kinases","Proto-Oncogene Proteins B-raf","Skin Neoplasms","Sulfonamides"],"meshMinor":["Antineoplastic Agents","Genes, ras","Humans","Indoles","Melanoma","Protein Kinase Inhibitors","Protein-Serine-Threonine Kinases","Proto-Oncogene Proteins B-raf","Skin Neoplasms","Sulfonamides"],"genes":["tyrosine kinase","serine-threonine and tyrosine kinases"],"publicationTypes":["Journal Article","Research Support, Non-U.S. Gov\u0027t","Review"],"abstract":"After years of therapeutic approaches with limited effects in metastatic melanoma, new inhibitors of serine-threonine and tyrosine kinases have demonstrated impressive clinical efficacy and improved survival.\nThis review explains the molecular background for the development of specific kinase inhibitors and briefly summarizes their clinical impact on advanced melanoma.\nDespite robust early clinical efficacy, the antiproliferative effect of these kinase inhibitors is limited. The resistance mechanisms are explored currently and will help to identify new targets for melanoma therapy.","title":"Resistance patterns with tyrosine kinase inhibitors in melanoma:  new insights.","pubmedId":"22316627"}